CoChat

Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant

Open access

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Abstract

Mutations in ESR1 have been associated with resistance to aromatase inhibitor (AI) therapy in patients with ER+ metastatic breast cancer. Little is known of the impact of these mutations in patients receiving selective oestrogen receptor degrader (SERD) therapy. In this study, hotspot mutations in ESR1 and PIK3CA from ctDNA were assayed in clinical trial samples from ER+ metastatic breast cancer patients randomized either to the SERD fulvestrant or fulvestrant plus a pan-PI3K inhibitor. ESR1 mutations are present in 37% of baseline samples and are enriched in patients with luminal A and PIK3CA -mutated tumours. ESR1 mutations are often polyclonal and longitudinal analysis shows distinct clones exhibiting divergent behaviour over time. ESR1 mutation allele frequency does not show a consistent pattern of increases during fulvestrant treatment, and progression-free survival is not different in patients with ESR1 mutations compared with wild-type patients. ESR1 mutations are not associated with clinical resistance to fulvestrant in this study.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms11579

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Distribution of ESR1 mutations and AF. (a) Distribution of ESR1 mutations detected in ctDNA from 153 part 1 patients. The bars indicate the number of patients for which each mutation was detected, and the percentage is relative to the total number of patients with mutations detected (57). Since multiple mutations were detected in 40% of the patients, the sum of the percentages is >100%. P535H and L536Q were not detected in any of the part 1 samples, but each was detected once among the 54 samples from part 2. V534E was not detected in any part 1 or part 2 sample. (b) Scatter plot of ESR1 and PIK3CA ctDNA mutation allele frequency (AF) for patients where both mutations were detected (n=34). The mutation AF sum is plotted for patients with multiple ESR1 or PIK3CA mutations.
Figure 1 Distribution of ESR1 mutations and AF. (a) Distribution of ESR1 mutations detected in ctDNA from 153 part 1 patients. The bars indicate the number of patients for which each mutation was detected, and the percentage is relative to the total number of patients with mutations detected (57). Since multiple mutations were detected in 40% of the patients, the sum of the percentages is >100%. P535H and L536Q were not detected in any of the part 1 samples, but each was detected once among the 54 samples from part 2. V534E was not detected in any part 1 or part 2 sample. (b) Scatter plot of ESR1 and PIK3CA ctDNA mutation allele frequency (AF) for patients where both mutations were detected (n=34). The mutation AF sum is plotted for patients with multiple ESR1 or PIK3CA mutations.CC BY · PubMed Central
Figure 2 PIK3CA and ESR1 mutation analysis of matched tissue and plasma samples. (a) PIK3CA and ESR1 mutation analysis of matched tumour tissue and plasma samples from 142 patients from part 1 of the clinical study. Mutations are coloured according to exon (PIK3CA) or amino acid (ESR1). Grey indicates mutations assessed were negative, and blank indicates data not available. (b) ESR1 tissue and matched plasma mutation status from 102 part 1 and part 2 patients. Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI on the right (81). Tissue collection at the time of primary or metastatic disease indicated with open or solid squares, respectively.
Figure 2 PIK3CA and ESR1 mutation analysis of matched tissue and plasma samples. (a) PIK3CA and ESR1 mutation analysis of matched tumour tissue and plasma samples from 142 patients from part 1 of the clinical study. Mutations are coloured according to exon (PIK3CA) or amino acid (ESR1). Grey indicates mutations assessed were negative, and blank indicates data not available. (b) ESR1 tissue and matched plasma mutation status from 102 part 1 and part 2 patients. Patients whose tissue was collected after receiving AI therapy shown on the left (21), and those whose tissue was collected before AI on the right (81). Tissue collection at the time of primary or metastatic disease indicated with open or solid squares, respectively.CC BY · PubMed Central
Figure 3 Kaplan–Meier plots of PFS in the fulvestrant and placebo part 1 patients. (a) PFS of ESR1 mutation (Mut.) status divided by one (red) or greater than one (green) mutation, or WT (blue). (b) PFS by ESR1 mutation AF less than (red) or greater than (green) the median AF. Hazard ratios are relative to WT for both plots. mo, months.
Figure 3 Kaplan–Meier plots of PFS in the fulvestrant and placebo part 1 patients. (a) PFS of ESR1 mutation (Mut.) status divided by one (red) or greater than one (green) mutation, or WT (blue). (b) PFS by ESR1 mutation AF less than (red) or greater than (green) the median AF. Hazard ratios are relative to WT for both plots. mo, months.CC BY · PubMed Central
Figure 4 Serial analysis of ctDNA mutation AF changes binned by best clinical response. (a) ESR1 and (b) PIK3CA ctDNA mutation AF changes while on part 1 (green) or part 2 (blue) pictilisib+fulvestrant or placebo+fulvestrant (grey) treatment arms. Patients are binned according to their best clinical response: CR/PR defined by RECIST criteria, and SD or PD as assessed by radiographic scans. Patients with a best response of non-CR/non-PD for patients without measurable disease at baseline are binned with SD. Each line represents one patient with the per cent change of AF relative to baseline (study day 0) plotted for two or three time points. The mutation AF sum is plotted for patients with multiple ESR1 (a) or PIK3CA (b) mutations.
Figure 4 Serial analysis of ctDNA mutation AF changes binned by best clinical response. (a) ESR1 and (b) PIK3CA ctDNA mutation AF changes while on part 1 (green) or part 2 (blue) pictilisib+fulvestrant or placebo+fulvestrant (grey) treatment arms. Patients are binned according to their best clinical response: CR/PR defined by RECIST criteria, and SD or PD as assessed by radiographic scans. Patients with a best response of non-CR/non-PD for patients without measurable disease at baseline are binned with SD. Each line represents one patient with the per cent change of AF relative to baseline (study day 0) plotted for two or three time points. The mutation AF sum is plotted for patients with multiple ESR1 (a) or PIK3CA (b) mutations.CC BY · PubMed Central
Figure 5 Clonal heterogeneity of ESR1 mutations. Dynamic changes in ctDNA mutation AF changes for six patients while on treatment as examples of clonal heterogeneity of ESR1 mutations. Each line represents a different ESR1 or PIK3CA mutation, and raw AF values are plotted for each time point. Patients 2310 and 6951 demonstrate divergent behaviour of mutations. Patients 4956, 4251, 6152 and 1653 demonstrate consistent increases and/or decreases of AF.
Figure 5 Clonal heterogeneity of ESR1 mutations. Dynamic changes in ctDNA mutation AF changes for six patients while on treatment as examples of clonal heterogeneity of ESR1 mutations. Each line represents a different ESR1 or PIK3CA mutation, and raw AF values are plotted for each time point. Patients 2310 and 6951 demonstrate divergent behaviour of mutations. Patients 4956, 4251, 6152 and 1653 demonstrate consistent increases and/or decreases of AF.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Research works printed but not linked: 1

  1. Krop, I. E. et al. Phase 2 randomised study of the PI3-kinase inhibitor pictilisib plus fulvestrant versus placebo plus fulvestrant in patients with oestrogen receptor-positive, aromatase inhibitor-resistant advanced or metastatic breast cancer: the FERGI trial. Lancet Oncol (in the press).

Cited by

See all 314

Metadata

Authors
Spoerke, J. M., Gendreau, S., Walter, K., Qiu, J., Wilson, T. R., Savage, H., Aimi, J., Derynck, M. K., Chen, M., Chan, I. T., Amler, L. C., Hampton, G. M., Johnston, S., Krop, I., Schmid, P., & Lackner, M. R.
Affiliations
  • Genentech (US)
  • Royal Marsden NHS Foundation Trust (GB)
  • Dana-Farber Cancer Institute (US)
  • Queen Mary University of London (GB)
Corresponding author
Lackner, Mark R.
Venue
Nature Communications
Published
2016-05-13
Volume
7
Issue
1
Pages
11579-11579
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2374277491
Cited by
309
References
41
Citations by year
2026: 20 · 2025: 21 · 2024: 14 · 2023: 30 · 2022: 27 · 2021: 37 · 2020: 28 · 2019: 42 · 2018: 36 · 2017: 41 · 2016: 12
FWCI
39.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Cancer Research UK
  • National Institute for Health and Care Research
Topics
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
ESR1 mutations, fulvestrant, PIK3CA mutation, circulating tumor DNA, clonal evolution, treatment resistance, pan-PI3K inhibitor, progression-free survival, luminal A
MeSH terms
Fulvestrant, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Breast, Breast Neoplasms, DNA Mutational Analysis, DNA, Neoplasm, Estradiol, Estrogens, Female, Humans, Indazoles, Middle Aged, Mutation, Sulfonamides, Disease-Free Survival, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, Estrogen Receptor alpha, Class I Phosphatidylinositol 3-Kinases, Estrogen Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.